What is the Alivus Life Sciences PE ratio today?
Alivus Life Sciences' PE ratio is 25.6 at the 29 October 2026 close (₹1,397.40 a share): a market capitalisation of ₹17,156 crore divided by consolidated net profit of ₹670 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY24 net profit (₹471 crore) it is 36.4.
What is the Alivus Life Sciences net worth?
Alivus Life Sciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹3,631 crore on 30 September 2026, up 20.4% from ₹3,015 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹17,156 crore at the 29 October 2026 close.
What is the Alivus Life Sciences book value per share?
Alivus Life Sciences' book value per share was ₹295.78 on 30 September 2026: shareholders' equity of ₹3,631 crore divided by the 12.28 crore shares in issue, up 20.3% from ₹245.79 a year earlier. The share price at the 29 October 2026 close was ₹1,397.40.
What is the Alivus Life Sciences PB ratio (price to book value)?
Alivus Life Sciences' price-to-book (PB) ratio is 4.72 at the 29 October 2026 close: a market capitalisation of ₹17,156 crore divided by shareholders' equity (book value) of ₹3,631 crore on 30 September 2026. That is a book value of ₹295.78 per share against a share price of ₹1,397.40.
What is the Alivus Life Sciences ROE and ROCE?
In FY24, Alivus Life Sciences' return on equity (ROE) was 21.1% and its return on capital employed (ROCE) was 26.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY23, ROE was 22.3% and ROCE 28.0%.
What is the Alivus Life Sciences dividend yield?
Alivus Life Sciences' dividend yield is 0.36% at the 29 October 2026 close: dividends of ₹5 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,397.40. They were ₹5 on 1 September 2026.
What is the Alivus Life Sciences market cap?
Alivus Life Sciences' market capitalisation was ₹17,156 crore at the 29 October 2026 close: 12.28 crore shares at ₹1,397.40 each.
Is Alivus Life Sciences debt free?
Yes. Alivus Life Sciences had no borrowings on 30 September 2026 (consolidated balance sheet), and it held ₹1,012 crore of cash, bank balances and current investments.
What is the Alivus Life Sciences dividend in 2026 and its record date?
In 2026, Alivus Life Sciences has declared one dividend: ₹5 with record date 1 September 2026.
What is the Alivus Life Sciences debt to equity ratio?
Alivus Life Sciences' debt-to-equity ratio was 0.00 on 30 September 2026: no borrowings against total equity of ₹3,631 crore. A year earlier, on 30 September 2025, it was 0.00.
What is the Alivus Life Sciences promoter holding?
Promoters held 74.85% of Alivus Life Sciences on 30 September 2026, down 0.02 percentage points from 74.87% the previous quarter and down 0.06 percentage points from 74.91% a year earlier, according to the shareholding pattern filed with NSE.
What is the Alivus Life Sciences revenue and profit in FY24?
In FY24 (April 2023–March 2024), Alivus Life Sciences' consolidated net profit was ₹471 crore, up 0.8% from ₹467 crore in FY23, on revenue from operations of ₹2,283 crore (up 5.6%).
What is the Alivus Life Sciences shareholding pattern?
On 30 September 2026, Alivus Life Sciences' shares were held by promoters 74.85%, foreign portfolio investors (FII/FPI) 5.93%, domestic institutions (DII) 7.03% (including mutual funds at 5.29%) and retail and other non-institutional investors 12.19%. Over the year, FII holding was down 0.91 percentage points from 6.84% and DII holding was up 1.56 percentage points from 5.47%.
What is the Alivus Life Sciences free cash flow?
In FY24, Alivus Life Sciences generated ₹414 crore of cash from operations and spent ₹129 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹285 crore. In FY23 it was ₹143 crore.
What are the Alivus Life Sciences latest quarterly results?
Alivus Life Sciences' latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit ₹197 crore, up 51.3% from ₹130 crore in Q2 FY26; revenue from operations ₹682 crore, up 16.0% year on year.
When are the Alivus Life Sciences next results?
Alivus Life Sciences has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
